Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS

Similar documents
Histological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis

Basement membrane in lobule.

Contents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ

Rare Breast Tumours. 1. Breast Tumours. 1.1 General Results. 1.2 Incidence

Triple Negative Breast Cancer

Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine

Recent advances in breast cancers

Morphological and Molecular Typing of breast Cancer

Rare types of breast carcinoma

Breast pathology. 2nd Department of Pathology Semmelweis University

Enterprise Interest None

Surgical Pathology Issues of Practical Importance

Molecular classification of breast cancer implications for pathologists. Sarah E Pinder

Protocol for the Examination of Biopsy Specimens From Patients With Invasive Carcinoma of the Breast

Present Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy

LYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR

XXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology

Papillary Lesions of the Breast: WHO Update

Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node

CLINICAL SIGNIFICANCE OF BENIGN EPITHELIAL CHANGES

UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF GENERAL MEDICINE DOCTOR S DEGREE THESIS ABSTRACT

BREAST PATHOLOGY. Fibrocystic Changes

Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק

Sentinel nodes. Location: Location: S1.04 Principal clinician. G1.01 Record other relevant information. S2.01 Number of specimens submitted

Diseases of the breast (2 of 2) Breast cancer

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein

The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach

AGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA DIAGNOSIS AND PROGNOSIS

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC

Neoplasias Quisticas del Páncreas

Oncologist. The. Breast Cancer. Management of Unusual Histological Types of Breast Cancer. The Oncologist 2012;17:

Case year old female presented with asymmetric enlargement of the left lobe of the thyroid

Case 4 Diagnosis 2/21/2011 TGB

2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING

ACRIN 6666 Therapeutic Surgery Form

Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up

Slide seminar. Asist. Prof. Jože Pižem, MD, PhD Institute of Pathology Medical Faculty, University of Ljubljana

BMaP-3 Cancer Database. Aggregate Data File

Papillary Lesions of the breast

Update in Salivary Gland Pathology. Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin

Radiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Results of the ACOSOG Z0011 Trial

CURRICULUM FOR THE BREAST PATHOLOGY ROTATION UNIVERSITY OF FLORIDA DEPARTMENT OF PATHOLOGY

Treatment options for the precancerous Atypical Breast lesions. Prof. YOUNG-JIN SUH The Catholic University of Korea

THYMIC CARCINOMAS AN UPDATE

Breast Cancer. Saima Saeed MD

IASLC 2011/WHO 2015 CLASSIFICATION OF LUNG ADENOCARCINOMAS

Mammographic imaging of nonpalpable breast lesions. Malai Muttarak, MD Department of Radiology Chiang Mai University Chiang Mai, Thailand

PRELIMINARY CYTOLOGIC DIAGNOSIS: Suspicious for Acinic Cell Carcinoma. Cell Block: Immunohistochemical Studies CYTOLOGIC DIAGNOSIS:

Los Angeles Society Of Pathologists Dr. Shobha Castelino Prabhu

PATHOBIOLOGICAL PREDICTORS OF BEHAVIOUR IN INVASIVE LOBULAR CARCINOMA OF THE BREAST. CHEOK POH YIAN (B.Sc., NUS) A THESIS SUBMITTED FOR THE DEGREE OF

Differential Diagnosis of Oral Masses. Palatal Lesions

Pancreatic Cytopathology: The Solid Neoplasms

Proliferative Breast Disease: implications of core biopsy diagnosis. Proliferative Breast Disease

Your Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:

04/10/2018. Intraductal Papillary Neoplasms Of Breast INTRADUCTAL PAPILLOMA

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

Papillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.

04/09/2018. Salivary Gland Pathology in the Molecular Era Old Friends, Old Foes, & New Acquaintances

Disclosures 5/27/2012. Outline of Talk. Outline of Talk. When Is LCIS Clinically Significant? Classic LCIS. Classic LCIS

Abid Irshad, MD Director Breast Imaging. Medical University of South Carolina Charleston

Ductal Carcinoma in Situ. Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA

One Breast Cancer Annual Report

Immunohistochemical classification of breast tumours

Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases

Objectives. Salivary Gland FNA: The Milan System. Role of Salivary Gland FNA 04/26/2018

December 2002 Monthly Memo

LOBULAR CARCINOMA IN SITU: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE

Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression

Benign Breast Disease and Breast Cancer Risk

Chapter 13 Cancer of the Female Breast

PET/CT in breast cancer staging

List of Available TMAs in the PRN

Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome

Breast Pathology. Breast Development

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Radiology- Pathology Conference 4/29/2012. Lymph Nodes. John McGrath

Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction

A712(19)- Test slide, Breast cancer tissues with corresponding normal tissues

Salivary gland neoplasms: an update 29th Annual Meeting of Arab Division of the International Academy of Pathology MUSCAT, OMAN 2017

Papillary Lesions of the Breast

Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.

K. M. Sorensen Utah State University, Logan, Utah

Prognostic and Predictive Factors

Hormone receptor and Her2 neu (Her2) analysis

Case study 1. Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research

Triple-negative breast cancer: which typical features can we identify on conventional and MRI imaging?

Salivary Glands 3/7/2017

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

They Do Look Alike : Mimics of Prostate Cancer in Biopsy Samples

Image guided core biopsies:

International Society of Gynecological Pathologists Symposium 2007

DOCTORAL THESIS SUMMARY

Case 1. ACCME/Disclosure. Clinical History. Dr. Mulligan has nothing to disclose

SFMC Breast Cancer Site Study: 2011

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Post Neoadjuvant therapy: issues in interpretation

The Hot Topic for today is a biopsy from a 58-year-old woman who had worrisome mammographic calcifications on screening.

Transcription:

Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS

Histological diversity of breast adenocarcinomas Different histological types are defined according to specific morphological and cytological patterns and are associated with distinctive clinical presentations The invasive ductal carcinoma not otherwise specified (IDC-NOS) or of no special type (IDC-NST) is the most common type IDC-NOS/NST is a diagnosis of exclusion, comprising adenocarcinomas without sufficient characteristics to warrant their classification in one of the special types

Histological Classification of Invasive Breast Cancer Type prevalence IDC NOS 65%-80% Invasive Lobular (Classical, Alveolar, Solid, Tubulo-lobular) 10%-15% Pure Tubular <2% Invasive Cribriform 1-3% Medullary (Typical, Atypical) 1-5% Mucinous 2% Neuroendocrine 2% Invasive Papillary <2% Invasive Micropapillary <2% Apocrine <2% Metaplastic <1% Lipid-rich Secretory Oncocytic Adenoid cystic 1% Acinic-cell Glycogen rich Sebaceous

Histology vs molecular classification Increased emphasis on immunohistochemical and genetic profile of tumors This approach pushes aside traditional descriptive definitions Immunohistochemichal classification often surrogate for molecular profiling used as Molecular classification established using a cohort of ductal carinoma NOS

Good prognosis group Tubular carcinoma Mucinous carcinoma Invasive cribriform carcinoma Solid neuroendocrine carcinoma Medullary carcinoma Adenoid cystic carcinoma Acinic cell carcinoma Secretory carcinoma (juvenile carcinoma)

Tubular carcinoma Readily mammographically detectable (spiculate nature, associated cellular stroma) Clinical charachteristics: Older patients, small T size, generally N0 Nearly always ER & PgR +, well-differentiated, and mostly HER2 - Survival is not significantly different from that of general population, even in case of N+

Mucinous carcinoma This group includes: - mucinous (colloid) carcinoma - mucinous cystadenocarcinoma - columnar cell mucinous carcinoma - signet ring cell carcinoma. Imaging challenge Most common at older age (median age at presentation 71 yrs); rare nodal involvement despite large tumor size Mostly Grade 1, ER and PgR positive and HER2

Invasive Cribriform Carcinoma Very few data on diagnostic imaging: low mammography sensitivity, US features not entirely typical of BC Generally ER+, HER2 negative, low grade 10-yr breast cancer specific survival is 100% for pure cribriform carcinomas Stutz JA et al, Clin Radiol 1994, 49:693-695; Page DL et al, Histopathology 1983, 7: 525-536

Medullary carcinoma Lower incidence of nodal involvement More likely to occur in younger patients (45-52yrs) At imaging may be confused with benign lesion Typically p53+, ER and HER2 negative, aneuploid, highly proliferative Growing data on correlation with BRCA1 mutation Good prognosis despite aggressive pathologic features

Adenoid Cystic Carcinoma Predominantly described in post-menopausal women Usually triple-negative phenotype, with low proliferation Metastases are rare, and have been reported to spread many years after primary diagnosis, and without prior nodal involvement Lung is the most frequent site of metastases, and patients may live many years with metastases Yerushalmi R, et al. Ann Oncol 2009, 20: 1763-1770; Arpino G et al. Cancer 2002, 94: 2119-2127

Apocrine Carcinoma Generally ER positive and PgR positive, with HER2 positivity reported in 50% of the cases Androgen receptor positivity in 56-100% Similar prognosis to IDC- NOS, when matched for stage and grade Pure Apocrine: ER and PgR negative, AR positive. Aggressive behaviour Weigelt B, et al. Molecular Oncology 2010; Yerushalmi R, et al. Ann Oncol 2009; Dellapasqua S, et al. Clin Breast Cancer 2013

Poor prognosis group Pleomorphic lobular cancer High-grade small-cell NE carcinoma Invasive micropapillary carcinoma Metaplastic carcinoma Lipid-rich carcinoma

Pleomorphic Lobular Cancer Weigelt B, et al. Molecular Oncology 4:192-208, 2010

Pleomorphic Lobular Cancer Very rare and distinct morphological variant of invasive lobular carcinoma, characterized by nuclear atypia and pleomorphism contrasted with the cytologic uniformity of ILC. Poor prognostic factors, including large tumor size, axillary node metastasis, poor histologic grade, HER 2+ in up to 30% of the cases This aggressive biology may be reflected in the poor clinical course of this subtype of lobular cancer Weigelt B, et al. Molecular Oncology 4:192-208, 2010

Invasive Micropapillary Carcinoma Weigelt B, et al. Molecular Oncology 4:192-208, 2010

Invasive Micropapillary Carcinoma Pure micropapillary carcinoma: 1% of breast cancers Mixed micropapillary carcinoma: up to 6% of breast cancers High density masses at mammography, with spiculated margins 70% are ER and PgR positive, 30-50% are HER2 positive Higher incidence of lymphovascular invasion and nodal metastases than invasive ductal carcinomas of no special type (up to 70% of the cases diagnosed with N+) Aggressive clinical behaviour

Metaplastic Carcinoma Weigelt B, et al. Molecular Oncology 4:192-208, 2010

Metaplastic Carcinoma Metaplastic carcinoma is usually diagnosed with T2 disease Commonly diagnosed in women >50 years of age. Most of them are high grade Triple negative features: 77-96% High metastatic potential. More than 50% of these tumors are associated with local or distal recurrence The spread is hematogenous rather than lymphatic Chemoresistant disease, with reported median OS from the onset of distant metastases of 8 months Hennessy B, et al. J Clin oncol 2005, 23:7827-7835; Pezzi CM, et al. Ann Surg Oncol 2007, 14:166-173

Uncommon histologies treatment recommendations Too rare to allow for dedicated randomized trials to determine optimal locoregional and systemic therapy Locoregional treatment recommendations are generally the same as for the IDC-NOS counterpart Many of the good prognosis group (tubular, medullary, cribriform and mucinous) have a very low risk of for regional lymphnodal involvement. However, there are no data to routinely support the omission of SNB Radiation therapy may be omitted in particularly good prognosis group (eg T1, tubular, no DCIS..) Partial breast irradiation might represent an interesting option

Systemic Treatment recommendations-nccn 2013

Systemic Treatment recommendations NCCN 2013

Heterogeneity of breast cancer: histotypes, molecular classification and immunohistochemical classification. Dieci MV et al, submitted